Opyl (ASX:OPL) - CEO, Michelle Gallaher
CEO, Michelle Gallaher
Sourced: Startup Daily
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Opyl (OPL) and the Association of Australian Medical Research Institutes have launched a social media guide to support medical researchers during COVID-19
  • Opyl has seen a 188 per cent increase in pandemic-related research findings being shared, as well as a 61 per cent increase in social media engagement since April
  • Opyl and AAMRI’s comprehensive guide will ensure that users are getting the right information from credible and knowledgeable sources
  • Company shares closed in the grey, trading for 7.3 cents each

Opyl (OPL) and the Association of Australian Medical Research Institutes (AAMRI) have launched a social media guide to support medical researchers during COVID-19.

Opyl is a social media technology company that specialises in the health and life-sciences industries.

Since the outbreak of COVID-19, Opyl has been monitoring online platforms. During this time, it has noted a 188 per cent increase in pandemic-related clinical and research findings being discussed and shared by medical researchers and healthcare professionals. Professionals in these fields have also been spending more time on social media sites than before.

According to Opyl, COVID-19 has seen a 61 per cent increase in social media engagement since the beginning of April.

“The need to disseminate trustworthy medical research, both quickly and broadly, has never been greater,” the company stated.

“It’s vital that Australian researchers know how to promote their research beyond the journals and ensure the new knowledge they’re creating gets noticed by a global audience. I hope our support helps Australian research go viral — for all the right reasons,” Opyl CEO Michelle Gallaher said.

Opyl and AAMRI’s comprehensive guide will ensure that users are getting the right information from credible and knowledgeable sources.

“For medical research institutes this is a real opportunity to share our knowledge and also demonstrate the huge amount of work we are undertaking for COVID-19 across Australia,” AAMRI President Professor Jonathan Carapetis AM said.

Company shares closed in the grey, trading for 7.3 cents each.

OPL by the numbers
More From The Market Online

ResMed spikes on robust results and global growth spurt

ResMed shares have climbed following the release of the company's strong Third Quarter FY2024 results.

PharmAust CEO’s sayanora triggers stock plunge

Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of…

Unith wraps up Q1 with $5M in cash as digital humans evolve

Unith has wrapped up Q1 of 2024 with nearly $5M in cash and opex reduced. But…

Recce wins safety board approval to dose 4g in R327 UTI infusion trial

Recce Pharma will dose patients with 4g of its R327 intravenous solution to treat UTIs in…